(Q36653920)

15 August 2017

1 reference

title

Advances in biologic therapy for ulcerative colitis and Crohn's disease (English)

1 reference

15 August 2017

0 references

1 reference

1

Geert D'Haens

0 references

author name string

Marco Daperno

series ordinal

2

1 reference

15 August 2017

1 December 2006

1 reference

Current gastroenterology reports

15 August 2017

1 reference

15 August 2017

8

1 reference

15 August 2017

6

1 reference

15 August 2017

506-512

1 reference

https://scigraph.springernature.com/pub.10.1007/s11894-006-0041-5

15 August 2017

0 references

cites work

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease

1 reference

12 December 2020

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

12 December 2020

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

12 December 2020

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

12 December 2020

Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study

1 reference

12 December 2020

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

1 reference

12 December 2020

Infliximab for ulcerative colitis: finally some answers

1 reference

12 December 2020

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

1 reference

12 December 2020

A preliminary study of growth hormone therapy for Crohn's disease

1 reference

12 December 2020

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

12 December 2020

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

12 December 2020

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial

1 reference

12 December 2020

Predictors of Crohn's disease

1 reference

12 December 2020

Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab

1 reference

12 December 2020

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

1 reference

12 December 2020

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

12 December 2020

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

1 reference

12 December 2020

Sargramostim for active Crohn's disease

1 reference

12 December 2020

Infliximab reverses growth hormone resistance associated with inflammatory bowel disease

1 reference

12 December 2020

Anti-interleukin-12 antibody for active Crohn's disease

1 reference

12 December 2020

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease

1 reference

12 December 2020

A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis

1 reference

12 December 2020

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.

1 reference

12 December 2020

A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis

1 reference

12 December 2020

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

12 December 2020

An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease

1 reference

12 December 2020

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

1 reference

12 December 2020

10.1007/S11894-006-0041-5

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17105690